Low-dose and high-dose aprotinin improve hemostasis in coronary operations

van Oeveren, 1987, Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass, Ann Thorac Surg, 44, 640, 10.1016/S0003-4975(10)62153-4

Royston, 1987, Effect of aprotinin on need for blood transfusion after repeat open-heart surgery, Lancet, 1, 1289, 10.1016/S0140-6736(87)91190-1

Bidstrup, 1989, Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol), J THORAC CARDIOVASC SURG, 97, 364, 10.1016/S0022-5223(19)34573-8

Blauhut, 1991, Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass, J THORAC CARDIOVASC SURG, 101, 958, 10.1016/S0022-5223(19)36611-5

van Oeveren, 1992, Anticoagulation policy during use of aprotinin in cardiopulmonary bypass, J THORAC CARDIOVASC SURG, 104, 210, 10.1016/S0022-5223(19)34859-7

Feindt, 1994, Is there a phase of hypercoagulability when aprotinin is used in cardiac surgery?, Eur J Cardiothorac Surg, 8, 308, 10.1016/S1010-7940(05)80091-0

Bidstrup, 1993, Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency, J THORAC CARDIOVASC SURG, 105, 147, 10.1016/S0022-5223(19)33859-0

Wildevuur, 1989, Platelet preservation during cardiopulmonary bypass with aprotinin, Eur J Cardiothorac Surg, 3, 533, 10.1016/1010-7940(89)90114-0

van Oeveren, 1990, Aprotinin protects platelets against the initial effect of cardiopulmonary bypass, J THORAC CARDIOVASC SURG, 99, 788, 10.1016/S0022-5223(19)36893-X

Havel, 1994, Aprotinin does not decrease graft patency after coronary bypass grafting despite reducing postoperative bleeding and use of donated blood, J THORAC CARDIOVASC SURG, 107, 807, 10.1016/S0022-5223(94)70336-1

Carrel, 1991, Low-dose aprotinin also allows reduction of blood loss after cardiopulmonary bypass, J THORAC CARDIOVASC SURG, 102, 801, 10.1016/S0022-5223(19)36879-5

Müller-Esterl, 1984, Monitoring of aprotinin plasma levels by an enzyme-linked immunosorbent assay (ELISA), Fresenius Z Anal Chem, 317, 718, 10.1007/BF00593873

Harder, 1991, Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator bypass, Ann Thorac Surg, 51, 936, 10.1016/0003-4975(91)91009-K

Edmunds, 1991, Invited letter concerning aprotinin, J THORAC CARDIOVASC SURG, 101, 1103, 10.1016/S0022-5223(19)36631-0

Kawasuji, 1993, Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary surgery, Ann Thorac Surg, 55, 1205, 10.1016/0003-4975(93)90035-G

Spannagl, 1994, High dose aprotinin reduces prothrombin and fibrinogen conversion in patients undergoing extracorporeal circulation for myocardial revascularization, Thromb Haemost, 72, 159, 10.1055/s-0038-1648829

Lu, 1991, Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol), Thromb Haemost, 66, 633, 10.1055/s-0038-1646477

Huang, 1993, Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery, J THORAC CARDIOVASC SURG, 106, 11, 10.1016/S0022-5223(19)33736-5

Havel, 1992, Aprotinin decreases release of 6-keto-prostaglandin F1α and increases release of thromboxane B2 in cultured human umbilical vein endothelial cells, J THORAC CARDIOVASC SURG, 104, 654, 10.1016/S0022-5223(19)34732-4

John, 1993, Reduction of heparin binding to and inhibition of platelets by aprotinin, Ann Thorac Surg, 55, 1175, 10.1016/0003-4975(93)90029-H

Royston, 1992, High-dose aprotinin therapy: a review of the first five years' experience, J Cardiothorac Vasc Anesth, 6, 76, 10.1016/1053-0770(91)90052-U

Patston, 1991, Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate, Biochemistry, 30, 8876, 10.1021/bi00100a022

Tabuchi N, de Haan J, Boonstra PW, van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J THORAC CARDIOVASC SURG1993;106:828-33.

Jansen, 1992, Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass, Ann Thorac Surg, 54, 744, 10.1016/0003-4975(92)91021-Z

Delrossi, 1989, Prophylactic treatment of postperfusion bleeding using epsilon aminocaproic acid, Chest, 96, 27, 10.1378/chest.96.1.27

Horrow JC, Hlavacek J, Strong MD, et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J THORAC CARDIOVASC SURG1990;99:70-4.

Wachtfogel, 1989, Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-α2-plasmin-inhibitor complexes during cardiopulmonary bypass, Blood, 73, 468, 10.1182/blood.V73.2.468.468

Eijsman, 1992, Cardiopulmonary bypass and haemostasis [Thesis], 64

de Smet AAEA, Chang Njoek Joen M, van Oeveren W, et al. Increased anticoagulation during cardiopulmonary bypass by aprotinin. J THORAC CARDIOVASC SURG1990;100:520-7.

Markwardt, 1991, Hirudin and derivatives as anticoagulant agents, Thromb Haemost, 66, 141, 10.1055/s-0038-1646383

España, 1989, Aprotinin (Trasylol) is a competitive inhibitor of activated protein C, Thromb Res, 56, 751, 10.1016/0049-3848(89)90292-2

Cosgrove, 1992, Aprotinin therapy for reoperative myocardial revascularization: a placebo controlled study, Ann Thorac Surg, 54, 1031, 10.1016/0003-4975(92)90066-D

Böhrer, 1990, Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin, J Cardiothorac Anesth, 4, 222, 10.1016/0888-6296(90)90241-7

Samama, 1994, Aprotinin could promote arterial thrombosis in pigs: a prospective randomized, blind study, Thromb Haemost, 71, 663, 10.1055/s-0038-1642500